Omega-6 Fatty Acid Level and Your Genetics

Linoleic acid (18:2), the most abundant omega-6 polyunsaturated fatty acid in the diet, circulates in the blood primarily as a component of phospholipids within lipoprotein particles. Genome-wide research has identified variants near SORT1, PCSK9, and APOE—genes central to hepatic LDL production and receptor-mediated lipoprotein clearance—as among the strongest genetic determinants of circulating linoleic acid (18:2) levels. This page explains how lipoprotein metabolism genetics shapes circulating omega-6 fatty acid concentrations, what the key research findings reveal, and how dietary patterns interact with inherited variation in fatty acid transport.

What is linoleic acid (18:2) level?

Linoleic acid (chemical notation 18:2n-6, indicating an 18-carbon chain with two double bonds in the omega-6 configuration) is classified as an essential fatty acid because the human body cannot synthesize it. The primary dietary sources are vegetable oils (sunflower, corn, soybean), nuts, and seeds.

After intestinal absorption, linoleic acid is packaged into chylomicrons for transport through the lymphatic system and into circulation. From there, it distributes across the lipoprotein spectrum—VLDL, LDL, and HDL particles—as part of their phospholipid shells and cholesteryl ester cores. The abundance of linoleic acid in the bloodstream therefore reflects not just dietary intake but the size, number, and clearance rate of the lipoprotein particles carrying it.

Circulating linoleic acid (18:2) levels measured in fasting plasma represent a composite of dietary omega-6 intake, hepatic lipoprotein production, and the efficiency of receptor-mediated particle clearance. Genetic variants in lipoprotein metabolism genes contribute meaningfully to these levels independently of diet.

Large-scale genome-wide research on linoleic acid (18:2) levels has identified multiple high-confidence genetic loci, with SORT1 and PCSK9—genes primarily characterized for their roles in LDL metabolism—emerging as top signals. This finding reflects that circulating linoleic acid levels are substantially determined by the abundance and clearance kinetics of the LDL particles that carry them. [1][2]

Because linoleic acid is context-dependent in its health implications—neither higher nor lower circulating levels carry a uniformly favorable interpretation—this result is most informative when considered alongside dietary fatty acid intake patterns and the complete lipoprotein profile.

Research base: Moderate.

The genetics behind linoleic acid (18:2) levels

Several high-confidence gene candidates emerge from the genomic signals most strongly associated with circulating linoleic acid (18:2) levels:

SORT1 (sortilin-1) is the top genetically prioritized gene at its associated chromosome 1 locus. Sortilin-1 is an intracellular sorting receptor in hepatocytes that regulates the secretion of apolipoprotein B-containing lipoproteins (VLDL and LDL precursors). Genetic variation at the SORT1 locus influences hepatic LDL particle output: variants that increase SORT1 expression are associated with lower LDL secretion and lower circulating LDL—and correspondingly, because linoleic acid is carried in LDL particles, lower circulating linoleic acid.

PCSK9 (proprotein convertase subtilisin/kexin type 9) encodes a serine protease that targets LDL receptors on hepatocytes for degradation. When PCSK9 is active, LDL receptors are broken down faster, reducing LDL clearance from circulation and increasing circulating LDL. Since LDL particles carry linoleic acid as part of their phospholipid content, higher PCSK9 activity is associated with more circulating LDL and correspondingly higher circulating linoleic acid. Conversely, PCSK9 loss-of-function variants are associated with lower LDL and lower linoleic acid levels.

APOE (apolipoprotein E) mediates the receptor-dependent hepatic uptake of triglyceride-rich lipoproteins and LDL. Genetic variation in APOE significantly affects lipoprotein clearance kinetics, and—by extension—the dwell time of dietary linoleic acid within circulating lipoprotein particles before hepatic uptake and metabolism.

SERPINA1 (alpha-1 antitrypsin) encodes a serine protease inhibitor primarily known for its role in lung and liver biology. Its presence among the highest-confidence genes at a linoleic acid locus likely reflects its lesser-characterized roles in lipoprotein metabolism and hepatic lipid handling rather than a direct fatty acid function.

Additional genes in associated genomic regions—including ABCA1 (a key regulator of cellular cholesterol efflux and HDL assembly) and ABCG8 (involved in intestinal sterol and fatty acid absorption)—point to the full absorption-to-clearance pathway as the genetic architecture governing linoleic acid (18:2) levels.

What the research says

Genome-wide metabolomics research has demonstrated that circulating omega-6 fatty acid levels are governed not only by desaturase enzymes (which determine conversion of dietary linoleic acid to downstream metabolites) but also by the lipoprotein transport machinery that determines how efficiently fatty acids move through the body.

The co-occurrence of SORT1, PCSK9, and APOE as top genetic signals for linoleic acid (18:2) levels confirms that LDL particle metabolism is a primary genetic axis for circulating omega-6 fatty acid variation—distinct from, but complementary to, the FADS desaturation pathway identified in other linoleic acid GWAS datasets. [1][2]

Key findings from this research context:

LDL clearance as an omega-6 determinant — the concentration of linoleic acid in plasma is partly a function of LDL particle abundance. Individuals with genetic variants that reduce LDL receptor activity (higher PCSK9 effect) or increase hepatic LDL output (different SORT1 haplotypes) tend to have more circulating LDL and correspondingly higher plasma linoleic acid—even at identical dietary intake.

ABC transporter biology and intestinal absorption — ABCA1 and ABCG8, both represented in the broader genetic footprint of this trait, are active at the intestinal epithelium and hepatocyte level in managing lipid efflux, bile acid recycling, and sterol absorption. Their co-occurrence with LDL clearance genes reflects the full systemic pathway from dietary fat absorption to plasma fatty acid distribution.

Genetic independence from diet — because the primary genetic signals for linoleic acid (18:2) levels operate through lipoprotein clearance rather than dietary intake or fatty acid desaturation, genetic predisposition toward higher or lower circulating linoleic acid is at least partly independent of how much linoleic acid a person consumes. This means that two individuals eating identical diets can have meaningfully different plasma linoleic acid profiles based on LDL metabolism genetics.

How linoleic acid (18:2) levels affect you

Circulating linoleic acid (18:2) levels are context-dependent: neither higher nor lower levels carry a straightforward health interpretation in isolation from the broader lipoprotein and fatty acid profile.

For individuals with genetic profiles associated with higher circulating linoleic acid through LDL pathway variants—more PCSK9 activity or less efficient SORT1-mediated LDL reduction—the elevated linoleic acid is part of a broader pattern of higher LDL particle burden. In this context, the relevant health consideration is less about linoleic acid per se and more about LDL-driven cardiovascular risk, where linoleic acid serves as a parallel marker of lipoprotein abundance.

Conversely, individuals with lower-activity PCSK9 variants or higher SORT1-mediated LDL reduction tend to have lower circulating linoleic acid as part of their overall lower LDL profile—which is generally associated with lower cardiovascular risk from that mechanism.

The context-dependent framing reflects the current understanding: linoleic acid itself is not the primary risk driver in this genetic architecture—the lipoprotein particles carrying it are. Understanding which genetic mechanisms are driving your linoleic acid level (lipoprotein clearance vs. dietary intake vs. desaturation efficiency) is more actionable than the level number in isolation.

Working with your linoleic acid (18:2) genetic profile

For individuals whose linoleic acid levels are primarily genetically driven by lipoprotein clearance pathways, the most relevant lifestyle interventions target LDL metabolism:

Saturated fat and dietary cholesterol most directly influence LDL particle production and circulating LDL, which in turn affects the linoleic acid carried within those particles. Reducing saturated fat intake from butter, fatty meats, and tropical oils while increasing unsaturated fats (including linoleic acid from olive oil, nuts, and seeds) supports lower LDL levels through multiple mechanisms.

Soluble fiber (oats, legumes, psyllium) reduces LDL by binding bile acids in the gut, prompting the liver to upregulate LDL receptors to compensate. This directly increases LDL clearance—the same pathway targeted by SORT1 and PCSK9 variants—making it particularly relevant for individuals with genetic profiles in these pathways.

Aerobic exercise increases hepatic LDL receptor activity and improves overall lipoprotein clearance efficiency. Regular moderate-intensity exercise consistently lowers LDL and shifts the LDL particle profile toward larger, less atherogenic particles.

Plant sterols and stanols (present in fortified foods and supplements) competitively inhibit intestinal cholesterol absorption, reducing LDL levels by 8–15 percent in controlled trials. Their mechanism involves the same intestinal absorption pathway where ABCG8 and ABCA1 function—relevant for individuals with variants in these genes.

Omega-3 supplementation addresses the omega-6 to omega-3 ratio concern that accompanies higher circulating omega-6 levels regardless of the underlying mechanism. EPA and DHA from fatty fish or supplements compete with arachidonic acid-derived pathways and support a more favorable inflammatory balance.

Related traits and genes

Linoleic acid (18:2) genetics connects to several closely related domains:

LDL cholesterol — SORT1, PCSK9, and APOE are the top genetic signals here and for LDL cholesterol, reflecting the shared lipoprotein pathway.

Omega-6 linoleic acid (FADS pathway) — a complementary linoleic acid genetic profile focused on the desaturation pathway rather than LDL transport.

Triglyceride levels — APOE and related lipoprotein genes drive both triglyceride and omega-6 fatty acid variation through shared metabolic routes.

HDL cholesterol — ABCA1 is a primary genetic determinant of HDL levels; its co-occurrence in linoleic acid genetics reflects shared lipoprotein biology.

Cardiovascular health — LDL pathway genes (SORT1, PCSK9) are among the most established cardiovascular genetics signals, linking this linoleic acid genetic profile directly to heart health genetics.

For a deeper look at SORT1's role in hepatic lipoprotein secretion, visit the SORT1 gene page. Learn how ExomeDNA interprets genetic research at our methodology page, and explore our approach with ExomeDNA Founder Scott Peeples.

Frequently asked questions

Why are LDL cholesterol genes like SORT1 and PCSK9 associated with linoleic acid levels? Linoleic acid circulates primarily as a component of LDL particle phospholipids and cholesteryl esters. Genes that affect LDL particle abundance—whether through hepatic LDL secretion (SORT1) or LDL receptor clearance (PCSK9)—also affect the total linoleic acid carried in those particles. Higher LDL particle burden from these genetic variants corresponds to higher circulating linoleic acid, independent of dietary omega-6 intake.

Is higher circulating linoleic acid (18:2) good or bad for health? It depends on the mechanism driving the level. When higher linoleic acid reflects higher LDL particle burden (through SORT1 or PCSK9 variants), the relevant health consideration is LDL-driven cardiovascular risk, where linoleic acid serves as a parallel marker. When higher linoleic acid reflects lower desaturation efficiency (through FADS variants), the implications are different. The level alone, absent the metabolic mechanism, does not have a simple favorable or unfavorable interpretation.

Does eating more linoleic acid necessarily raise my circulating 18:2 level? Not proportionally. Because a major genetic driver of circulating linoleic acid (18:2) is LDL particle metabolism rather than dietary intake, two individuals eating the same amount of linoleic acid can have different plasma levels based on their LDL clearance genetics. Dietary intake does contribute to plasma linoleic acid, but genetic variation in lipoprotein handling means the relationship between diet and plasma level is modified substantially by genetic background.

What is SORT1 and what does it do in lipid metabolism? SORT1 encodes sortilin-1, an intracellular sorting receptor in hepatocytes that participates in packaging and secreting apolipoprotein B-containing lipoproteins (LDL and VLDL precursors). Genetic variants near SORT1 influence hepatic LDL output: higher SORT1 expression is associated with reduced LDL secretion, lower circulating LDL, and lower circulating linoleic acid. SORT1 was one of the first genome-wide association loci identified for LDL cholesterol and has been consistently replicated across ancestries.

How does ABCA1 relate to this linoleic acid profile? ABCA1 (ATP-binding cassette transporter A1) mediates the efflux of cholesterol and phospholipids from cells to lipid-poor apolipoprotein A-I, the first step in HDL assembly. At the intestinal level, ABCA1 also participates in regulating fatty acid absorption into enterocytes. Its co-occurrence with LDL clearance genes in the linoleic acid (18:2) genetic architecture reflects the multistep nature of dietary fatty acid handling—from intestinal absorption through lipoprotein transport to hepatic clearance.

References

1. Genome-wide association study of linoleic acid (18:2) levels (2023). PMID: 37255970.
2. Genome-wide metabolomics study of circulating fatty acid levels (2023/2024). PMID: 38448586.

Data sources: GWAS Catalog, Open Targets Genetics, ClinVar, ClinGen, NCBI Gene, dbSNP.